SCHEMBL6324586

SCHEMBL6324586

CC(=O)Oc1cc(C=O)ccc1OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 2/20 0.55
LMNA P02545 1/20 0.55
PTPN1 P18031 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
TACR2 P21452 1/20 0.52
APP P05067 5/20 0.52
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
HPGD P15428 2/20 0.49
HTT P42858 1/20 0.49
AKR1C3 P42330 1/20 0.48
NPC1 O15118 1/20 0.48
CYP2C9 P11712 1/20 0.48
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
POLB P06746 1/20 0.48
UBE2N P61088 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23085881 0.95 ALDH1A1 (0.57) ALDH1A1KDM4ELMNAPTPN1SMN1; SMN2
SCHEMBL29446267 0.85 TACR2 (0.62) ALDH1A1KDM4ELMNASMN1; SMN2TACR2
SCHEMBL584489 0.85 TACR2 (0.62) ALDH1A1KDM4ELMNASMN1; SMN2TACR2
SCHEMBL161066 0.83 ALDH1A1 (0.73) ALDH1A1KDM4ESMN1; SMN2APPHPGD
Anisaldehyde SCHEMBL8699445 0.82 PDCD1 (0.53) ALDH1A1KDM4ESMN1; SMN2APPHTT
SCHEMBL4363943 0.82 MAOB (0.57) ALDH1A1PTPN1SMN1; SMN2MAOBHPGD
SCHEMBL22116364 0.82 PTPN1 (0.60) ALDH1A1PTPN1SMN1; SMN2HPGDNPC1
SCHEMBL16294326 0.82 ALDH1A1 (0.55) ALDH1A1KDM4ESMN1; SMN2APPNPC1
SCHEMBL662145 0.82 TACR2 (0.75) ALDH1A1KDM4ELMNASMN1; SMN2TACR2
SCHEMBL1609108 0.82 TACR2 (0.75) ALDH1A1KDM4ELMNASMN1; SMN2TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050228017-A1 Novel anticancer compounds MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE 2005-10-13 US disclosed
US-6870035-B2 Black dye mixtures of fiber-reactive azo dyes, methods for their preparation and use thereof for dyeing hydroxy-and/or carboxamido-containing fiber material DYSTAR TEXTILFARBEN GMBH & CO. DEUTSCHLAND KG (DE) 2005-03-22 US disclosed
EP-1442018-A1 NOVEL ANTICANCER COMPOUNDS Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) 2004-08-04 EP disclosed
WO-2003037865-A1 NOVEL ANTICANCER COMPOUNDS Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228017-A1 Novel anticancer compounds TP53, ABCG2, MCL1 ALDH1A1 211/4885KDM4E 2416/4885LMNA 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.